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and 7,668 euros respectively. For the replacement
approach the costs for severe, moderate and mild patients
were 25,333, 16,631, and 9,932 euros respectively. 
Informal support and costs, in terms of ADL, IADL,
Social/recreation and Behaviour increased with Alzheimer
severity. CONCLUSIONS: This study gives some new
perspectives on informal care giving for persons with
Alzheimer. Informal care for Alzheimer represent a sig-
niﬁcant hidden cost to Spanish society. This aspect of
caring must be addressed by the development of well-
targeted respite and relief support programmes. Because
the Spanish community is rapidly aging, this informal
care burden may increase signiﬁcantly in the future.
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OBJECTIVES: Placebo-controlled clinical trials have
demonstrated the efﬁcacy of memantine versus placebo in
moderately severe and severe Alzheimer’s disease. A mod-
elling approach has been adopted to estimate costs and
outcomes of memantine treatment in clinical practice in
Spain. METHODS: A Markov model simulated moder-
ately severe and severe patients’ progression through
levels of combinations of severity, autonomy, and setting
over ﬁve years. Model inputs include clinical trial results
and measurement of patient and caregiver resource utili-
sation from a societal perspective using literature and
expert data. The main outcome measures were time spent
in autonomy (patient’s ability to accomplish activities
using the ADCS-ADL scale) and time to institutionalisa-
tion. This cost-effectiveness study compared the meman-
tine treatment strategy to that of no pharmacotherapy
and to donepezil for patients with moderately severe AD
followed by no pharmacotherapy when patients reach the
severe AD level. RESULTS: The time spent in autonomy
for patients treated with memantine is 14% longer in
duration than for patients treated with donepezil and
25% longer than for patients without pharmacotherapy.
The delay time to institutionalisation was 8% longer with
memantine compared with donepezil and 12% longer
with memantine compared with no treatment. Over a 5-
year period, patients treated with memantine showed a
decrease of €268 and €511 in total Health care costs,
compared with donepezil and no treatment, respectively.
Robustness of the results was validated by a comprehen-
sive sensitivity analysis. CONCLUSION: Memantine is
more effective in increasing time spent in autonomy and
in reducing Health care costs compared with donepezil or
no pharmacotherapy.
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OBJECTIVES: To assess the impact of DBS of the STN
on HRQOL and on Health care resource use in French
advanced parkinsonian patients and to estimate the cost
of the procedure. METHODS: SPARK is an observational
prospective multicentre study using a before-after
methodology carried out between November 1998 and
March 2002 in a cohort of 88 patients with severe Parkin-
son’s disease (PD). Quality of life was assessed before
surgery and at 12-month follow-up using a speciﬁc instru-
ment, the PDQL 37 (Parkinson’s Disease Quality of Life)
that has a 3-month recall period. The resource use data
were monthly collected from individual questionnaires.
Two periods of observation were considered: the ﬁrst 6
months prior surgery and from the 6th to the 12th month
after surgery. The cost of the procedure (surgery, mater-
ial and checkups over 1 year) was assessed from data 
collected in the 4 centres. The economic analysis was 
performed from a Health Insurance perspective.
RESULTS: About 66% of patients were men. The mean
age of patients was 57.3 ± 7.7 years with a mean dura-
tion of PD of 13.9 ± 5.0 years. At 12-month follow-up
after surgery, the quality of life was signiﬁcantly improved
(+28%, p < 0.0001). All the PDQL subscores were con-
cerned by this improvement, especially the social dimen-
sion (+43.5%, p < 0.0001). The average 6-monthly cost
decreased from €10,087 ± 4,887 prior surgery to €1,673
± 2,111 after surgery (€-8,415 ± 4,438, p < 0.0001).
Taking into account costs related to adjustments of the
parameters of the stimulator, the difference was reduced
but remained signiﬁcant: €-7,275 ± 5,128 (p < 0.0001).
The most important savings came from a dramatically
decrease in medication use. CONCLUSIONS: Our ﬁnd-
ings showed a signiﬁcant impact of DBS on HRQOL and
on medical resource use in patients with PD.
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OBJECTIVES: The purpose was to develop an early 
decision-making model for Parkinson disease (PD) and 
to assess the cost-effectiveness of neural transplanta-
tion (NT) compared to standard treatment in PD.
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METHODS: Clinical data from 79 PD patients and data
from the literature regarding PD-related costs, clinical
progression and life expectancy were used to develop a
disease progression model according to the Hoehn and
Yahr stage of PD (HY). The model was designed to model
both protective and symptomatic treatment effects. Out-
comes were based on a consecutive series of 14 PD
patients treated with intrastriatal NT of human embry-
onic mesencephalic tissue, and followed for 2–10 years
thereafter. Since the majority of patients receiving NT had
early onset PD and were in HY 3–4, the cost-effectiveness
of NT was evaluated for patients belonging to these cat-
egories. Costs and quality adjusted life years (QALY)
were calculated for a period of 25 years and discounted
at 3%. The calculations were made in Euro (€) (2002
prices). A sensitivity analysis was performed where sce-
narios regarding treatment effect, time horizon, discount
rate, and the procedure cost were altered. RESULTS:
Patients with a preoperative HY state of 3 and 4
improved 0.552 and 0.736 HY stages following NT,
which is equivalent to 4.9 and 6.6 years in less advanced
PD stages, respectively. The cost of NT, including
expected costs of complications, was €36,000. The incre-
mental cost-effectiveness ratio of NT compared to stan-
dard treatment was €11,400 for patients in HY 3 and cost
saving in HY 4 patients. CONCLUSIONS: According to
the assumptions made in the model, NT is cost-effective
compared to standard treatment in Sweden. The main
conclusions were insensitive to the assumptions made in
the sensitivity analysis.
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OBJECTIVES: Parkinsonian syndromes (PS) can be difﬁ-
cult to diagnose clinically, the most common condition
misdiagnosed as PS being essential tremor (ET).
DaTSCAN (123I-FP-CIT) SPECT imaging accurately 
differentiates PS with dopaminergic deﬁcit from ET 
in patients with uncertain clinical diagnosis (sensitivity
95%, speciﬁcity 93%). This study aimed to assess the eco-
nomic value of using DaTSCAN to the Belgian Health
care system. METHODS: A Markov model was devel-
oped to simulate a cohort of patients with clinically
uncertain PS managed over 5 years 1) without DaTSCAN
(treatment based on clinical judgement), or 2) all patients
receiving DaTSCAN at the outset. Health states were
deﬁned by type of therapy (PS ﬁrst-line, PS second-line,
ET, none) and underlying condition (PS, ET). The model
estimated time on appropriate therapy (PS therapy for
underlying PS, ET therapy for underlying ET) and patient
management costs. Model inputs were from published
studies, with treatment patterns/resource use from a
Delphi panel of 13 Belgian physicians. 53% cohort
members were assumed to have true PS. Costs were from
ofﬁcial sources, the test cost (agent plus administration)
being €900. RESULTS: Without DaTSCAN, 41% of
cohort members were treated appropriately at the outset,
rising to 75% at 5 years. Using DaTSCAN, 94% of
patients were treated appropriately at the outset, declin-
ing to 77% at 5 years. DaTSCAN use generated an incre-
mental 1.40 “adequately treated years” at a net cost of
€140 per patient. This result was sensitive to the under-
lying prevalence of PS, but relatively robust to variations
in other model parameters, such as rates of adverse events
and withdrawal from therapy. CONCLUSION: Treat-
ment of patients with clinically uncertain PS based on
DatSCAN rather than clinical judgement may be consid-
ered to be an economically favourable strategy. An
increase in time on appropriate therapy is achieved at
modest extra cost to the Health care system.
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The management of a chronic disease must integrate the
needs induced by the disease on the patient’s surround-
ings. OBJECTIVE: The TRILOGIE study was initiated by
a group of neurological and neuro-paediatric experts and
the Ligue Francaise Contre l’Epilepsie to study the Child-
Parent-Epilepsy interaction. The objective is to assess the
socio-economic consequences of epilepsy on the daily life
of the parents of a child diagnosed as epileptic for more
than six months. METHODS: Self-administered ques-
tionnaires, created on the basis of interviews with fami-
lies of epileptic children, were sent to paediatricians and
neuro-paediatricians taking care of epileptic children, as
well as to members of patients’ associations. They then
distributed them to the parents of the children concerned.
RESULTS: The results concerned a population of 668
parents of epileptic children. Eight domains were
explored as part of the study. The management of the
disease is often difﬁcult with more than one hospitalisa-
tion (70% of the children). The consequences for the chil-
dren are serious difﬁculties at school (40%) and a greater
need for care (63%). Medical and/or psychological help
is therefore often needed by the parents (38%). Epilepsy
is source of conﬂict for 43% of the couples. The major
economic impact of the disease is due to partial reim-
bursement of nursing costs, extra costs of care and
schooling and loss of revenue due to one parent giving up
full time work. CONCLUSIONS: TRILOGIE underlines
the parent’s need for information concerning: the current
and future treament of the disease, the possibilities of sco-
larisation and the concrete daily help.
